These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The Role of Hypofractionated Radiotherapy in Prostate Cancer. Benjamin LC; Tree AC; Dearnaley DP Curr Oncol Rep; 2017 Apr; 19(4):30. PubMed ID: 28343352 [TBL] [Abstract][Full Text] [Related]
5. Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists. McClelland S; Sandler KA; Degnin C; Chen Y; Hung AY; Mitin TE Int Braz J Urol; 2019; 45(2):273-287. PubMed ID: 30676300 [TBL] [Abstract][Full Text] [Related]
6. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529 [TBL] [Abstract][Full Text] [Related]
7. Hypofractionation for prostate cancer: an update. Tiberi D; Vavassis P; Nguyen D; Yassa M Expert Rev Endocrinol Metab; 2017 May; 12(3):199-205. PubMed ID: 30063454 [TBL] [Abstract][Full Text] [Related]
8. Moderate Hypofractionated Radiotherapy for Localized Prostate Cancer: The Triumph of Radiobiology. Kougioumtzopoulou A; Platoni K; Zygogianni A; Kounadis G; Syrigos KN; Psyrri A; Bamias A; Kelekis N; Kouloulias V Rev Recent Clin Trials; 2021; 16(4):351-371. PubMed ID: 33966623 [TBL] [Abstract][Full Text] [Related]
9. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287 [TBL] [Abstract][Full Text] [Related]
10. A systematic review of hypofractionation for primary management of prostate cancer. Koontz BF; Bossi A; Cozzarini C; Wiegel T; D'Amico A Eur Urol; 2015 Oct; 68(4):683-91. PubMed ID: 25171903 [TBL] [Abstract][Full Text] [Related]
11. Hypofractionated Radiotherapy for Localized Prostate Cancer: A Challenging Accelerated Hypofractionated Radiotherapy. Yamazaki H; Nakamura S; Suzuki G; Yoshida K; Yoshioka Y; Koizumi M; Ogawa K Anticancer Res; 2015 Oct; 35(10):5167-77. PubMed ID: 26408674 [TBL] [Abstract][Full Text] [Related]
12. Hypofractionated and hyper-hypofractionated radiation therapy in postoperative breast cancer treatment. Fang M; Marta GN Rev Assoc Med Bras (1992); 2020 Sep; 66(9):1301-1306. PubMed ID: 33027462 [TBL] [Abstract][Full Text] [Related]
13. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359 [TBL] [Abstract][Full Text] [Related]
14. Ultrahypofractionation of localized prostate cancer : Statement from the DEGRO working group prostate cancer. Wolf F; Sedlmayer F; Aebersold D; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Ghadjar P; Höcht S; Hölscher T; Müller AC; Niehoff P; Pinkawa M; Schmidt-Hegemann NS; Zamboglou C; Zips D; Wiegel T Strahlenther Onkol; 2021 Feb; 197(2):89-96. PubMed ID: 33301049 [TBL] [Abstract][Full Text] [Related]
15. Systematic review of hypofractionated radiation therapy for prostate cancer. Zaorsky NG; Ohri N; Showalter TN; Dicker AP; Den RB Cancer Treat Rev; 2013 Nov; 39(7):728-36. PubMed ID: 23453861 [TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of moderate hypofractionation with volumetric modulated arc therapy versus conventional 3D-radiotherapy after radical prostatectomy. Moll M; D'Andrea D; Zaharie A; Grubmüller B; Paschen C; Zehetmayer S; Shariat SF; Widder J; Goldner G Strahlenther Onkol; 2022 Aug; 198(8):719-726. PubMed ID: 35284951 [TBL] [Abstract][Full Text] [Related]
17. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116 [TBL] [Abstract][Full Text] [Related]
18. Hypofractionated radiotherapy recommendations for localized prostate cancer in Brasil. Palhares DMF; Pimentel LCF; Castilho MS; Costa ABD; Reisner ML; Kuhnen FQ; Pássaro A; Leite ETT; Faustino FLC; Obst FM; Costa FNBBF; Pioner GT; Carvalho ÍT; Silva JLFD; Morikawa LKK; Zanuncio PHDR; Hanriot RM; Rosa AA Rev Assoc Med Bras (1992); 2021 Jan; 67(1):7-18. PubMed ID: 34161478 [TBL] [Abstract][Full Text] [Related]
19. Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations. Sanfilippo NJ; Cooper BT Am J Clin Exp Urol; 2014; 2(4):286-93. PubMed ID: 25606574 [TBL] [Abstract][Full Text] [Related]
20. Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Meta-analysis of Randomized Noninferiority Trials. Royce TJ; Lee DH; Keum N; Permpalung N; Chiew CJ; Epstein S; Pluchino KM; D'Amico AV Eur Urol Focus; 2019 Jul; 5(4):577-584. PubMed ID: 29221876 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]